The trial NCT00965224 demonstrated that WT1 mRNA-electroporated DCs could prevent or delay relapse in 43% of high-risk AML patients and improved 5-year overall survival (OS) compared to population registry data. This evidence concerns the gene WT1 and acute myeloid leukemia.